ClinConnect ClinConnect Logo
Search / Trial NCT07090382

Prospective Validation of the STOPSHOCK Score - Artificial Intelligence Based Predictive Scoring System to Identify the Risk of Developing Cardiogenic Shock (CS) in Patients Suffering From Acute Coronary Syndrome (ACS)

Launched by PREMEDIX ACADEMY · Jul 24, 2025

Trial Information

Current as of August 20, 2025

Enrolling by invitation

Keywords

Cardiogenic Shock Acute Coronary Syndrome Risk Prediction Clinical Decision Support Emergency Medicine Coronary Care Unit Shock Prevention Prognostic Score Cardiovascular Disease Predictive Modeling Early Warning System Intensive Care Mortality Risk Prospective Validation

ClinConnect Summary

Cardiogenic shock is a serious life-threatening condition affecting almost 10% of patients suffering from acute coronary syndrome (ACS). When untreated, it can rapidly progress to collapse of circulation and sudden death. Despite recent improvements in diagnostic and treatment options, mortality remains incredibly high, reaching nearly 50%. Currently available mechanical circulatory support devices can replace the function of the heart and/or lungs, thereby essentially eliminating the primary cause. However, cardiogenic shock is not only an isolated decrease in cardiac function but a rapidl...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients aged \>18 years.
  • Admitted for acute coronary syndrome in CCU
  • Exclusion Criteria:
  • Patients aged \< 18 years.
  • Patients in CSWG-SCAI C, D or E CS the before the admission to CCU.

About Premedix Academy

Premedix Academy is a pioneering clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative study designs and robust methodologies. With a focus on education and training for healthcare professionals, Premedix Academy leverages its expertise to facilitate the development of cutting-edge therapies across various therapeutic areas. The organization emphasizes ethical practices, patient safety, and regulatory compliance, ensuring that all trials are conducted to the highest standards. By fostering collaboration among stakeholders, including researchers, clinicians, and patients, Premedix Academy aims to contribute significantly to the advancement of medical science and the enhancement of healthcare solutions.

Locations

Bratislava, , Slovakia

Patients applied

0 patients applied

Trial Officials

Allan Böhm, MD, PhD, MSc, MBA, FESC, FJCS

Principal Investigator

Premedix Academy

Branislav Bezák, MD, PhD

Study Director

Premedix Academy

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported